Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
- Written by PR Newswire
- Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year
- Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics
- Promising efficacy results in cardiovascular performance observed in Cohort A...













